The government on Monday unveiled the sixth batch of strategic enterprises that wish to establish or expand their presence in Hong Kong, including biopharmaceutical giant, Pfizer, as well as biotech firm Amgen.
Both of the firms are valued at over HK$1 trillion, and other medical firms on the list include Germany’s Boehringer Ingelheim…
阅读更多（Read More）